Results 61 to 70 of about 7,551 (201)

A scoring model predicts hepatitis B e antigen seroconversion in chronic hepatitis B patients treated with nucleos(t)ide analogs: real-world clinical practice

International Journal of Infectious Diseases, 2017
Aim: This study developed and validated a non-invasive scoring model to predict 1-year hepatitis B e antigen (HBeAg) seroconversion in response to nucleos(t)ide analog (NA) treatment in NA-naïve patients with HBeAg-positive chronic hepatitis B (CHB ...
Mingfan Geng, Yuxin Li, Fangyuan Gao, Le Sun, Xue Yang, Rui Wang, Jialiang Chen, Qun Zhang, Gang Wan, Xianbo Wang   +9 more
doaj   +1 more source

HBV RNA Predicts the Risk of Off‐Treatment Relapse in Chronic Hepatitis B Patients With NAs Therapy: A Systematic Review and Meta‐Analysis [PDF]

J Viral Hepat
ABSTRACT Since there are currently few antiviral drugs that can effectively reduce hepatitis B surface antigen levels, the recurrence rate remains high in patients with chronic hepatitis B (CHB) after discontinuing nucleoside analogues (NAs) treatment.
Wang D, Wang J, Jiang S, Zhou A, Jin M, Zhang H, Yang S, Fan S, Hu A.   +8 more
europepmc   +2 more sources

Serum Interleukin-37 Concentrations and HBeAg Seroconversion in Chronic HBV Patients During Telbivudine Treatment [PDF]

Journal of Interferon & Cytokine Research, 2013
IL-37 is a new anti-inflammatory cytokine that plays an important role in protecting against tissue injury during infections via limiting immune and inflammatory reactions. This study aimed at determining serum IL-37 concentrations and HBeAg seroconversion in chronic hepatitis B virus (HBV) patients during Telbivudine (LDT) treatment.
Cong, Li, Huifan, Ji, Yanjun, Cai, Desalegn Admassu, Ayana, Pin, Lv, Maosheng, Liu, Yanfang, Jiang   +6 more
openaire   +2 more sources

The Serumal Concentration of Hbsag in Patiets with Chb/hiv Co-infection Comparing with Chb Mono-infection in the Different Phases of Natural Course of Chronic Hepatitis В [PDF]

, 2016
The prevalence and inclination to chronization of viral hepatitis B is 3 – 5 times higher in patients with HIV-infection than in HIV-negative ones. The natural clinical course of chronic hepatitis B (CHB) in patients with HIV has the features, connected ...
Melnyk, T. (Tetiana), Moroz, L. (Larisa)
core  

Chronic Hepatitis B in Pregnancy: Quantitative HBsAg, Genotype and HBeAg Seroconversion

, 2022
HBsAg quantification may be a potential surrogate marker for hepatitis B (HBV) DNA load in mothers with chronic hepatitis B (CHB) given the higher availability and cheaper cost. Although genotype is not routinely tested in clinical practice, there are no studies looking at whether a correlation between quantitative HBsAg (qHBsAg) and viral load is ...
openaire   +2 more sources

Prevalence and Risk Factors of Elevated Alanine Aminotransferase (ALT) in 2382 Treatment‐naïve HBV/HDV Co‐Infected Patients

Liver International, Volume 46, Issue 4, April 2026.
ABSTRACT Background Chronic hepatitis D (CHD) causes severe chronic hepatitis. Knowledge is limited about factors correlating with ALT in treatment‐naïve patients with CHD. This study analysed the pattern and determinants of ALT elevation in a large cohort of patients with CHD, including young adults, compared to propensity score‐matched (PSM) patients
Habiba Kamal, Ganbolor Jargalsaikhan, Sanjaasuren Enkhtaivan, Karin Lindahl, Hannes Hagström, Daniel Bruce, Michael Ingre, Bekhbold Dashtserenx, Oyungerel Lkhagva‐Ochir, Tuvshinjargal Ulziibadrakh, Andreas Bungert, Heiner Wedemeyer, Naranjargal B. Dashdorj, Soo Aleman   +13 more
wiley   +1 more source

Treatment of Chronic Hepatitis B with Interferon: Long Term Follow-Up

Canadian Journal of Gastroenterology, 1996
The aim of treatment of chronic hepatitis B with interferon is to induce a transition from the replicative phase of the disease to a nonreplicative state, with loss of hepatitis B virus (HBV)-DNA, seroconversion from hepatitis B e antigen (HBeAg ...
Jean-Pierre Villeneuve, Bernard Willems
doaj   +1 more source

Vaccines at the Heart of Hepatitis Elimination: Insights From the ESCMID Study Group for Viral Hepatitis (ESGVH)

Liver International, Volume 46, Issue 4, April 2026.
ABSTRACT The global elimination of viral hepatitis by 2030 remains an ambitious goal that hinges not only on diagnostics and therapeutics but fundamentally on the strategic use and continued innovation of vaccines. The ESCMID Study Group for Viral Hepatitis (ESGVH) convened to examine the role of vaccination as the cornerstone of hepatitis prevention ...
Oana Săndulescu, Gülşen Özkaya Şahin, Susanne Gjeruldsen Dudman, Zeinab Nabil Ahmed Said, Mario U. Mondelli, on behalf of ESCMID Study Group for Viral Hepatitis (ESGVH)   +5 more
wiley   +1 more source

Hepatitis B virus genotype distribution and genotype-specific BCP/preCore substitutions in acute and chronic infections in Argentina. [PDF]

PLoS ONE, 2015
In order to assess Hepatitis B Virus genotype (g) and subgenotype (sg) implications in the course of infection, 234 HBsAg positive patients in different infection stages were characterized (66 acute infections, 63 HBeAg positive chronic infections and ...
María Mora González López Ledesma, Laura Noelia Mojsiejczuk, Belén Rodrigo, Ina Sevic, Lilia Mammana, Omar Galdame, Adrian Gadano, Hugo Fainboim, Rodolfo Campos, Diego Flichman   +9 more
doaj   +1 more source

Seroprevalence Of Hepatitis-b Virus In Mid And Far Western Region In Nepal [PDF]

, 2012
Hepatitis B is significant health problems that might involve the late sequel of liver cirrhosis and hepatocellular carcinoma. The present study aimed to know the seroprevalence of hepatitis B virus (HBV) in mid and far western region in Nepal with ...
H, S. A. (Siddiqui), M, A. (Ansari), P, S. (Singh), S, K. (Khan)   +3 more
core